Wednesday, April 1, 2015

Drugs in Clinical Pipeline: Daprodustat

Daprodustat [2-(1,3-dicyclohexyl-2,4,6-triohexahydropyrimidine-5-carboxamide acetic acid] is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs). This compound is being developed for the treatment of anemia. It is being developed by GlaxoSmithKline.

Common Name: Daprodustat
Synonyms: GSK1278863; 1278863; GSK-1278863; GSK-1278863A
IUPAC Name: 2-(1,3-dicyclohexyl-2,4,6-triohexahydropyrimidine-5-carboxamide acetic acid
CAS Number: 960539-70-2
Mechanism of Action: Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
Indication: Anemia, Diabetic wounds
Development Stage: Phase I/II
Company: GlaxoSmithKline

1. Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers. NCT02293148